English Funding For Aquipta Targets AbbVie’s Migraine Drug To 170,000 People

 
• By Neena Brizmohun

Aquipta is the first oral treatment that NICE has recommended for preventing chronic migraines in the fourth-line setting, and the second oral treatment for episodic migraines in the same setting. The drug has already secured reimbursement in Scotland, Sweden and Israel.

Pfizer biohaven migraine deal
Aquipta is an oral, once-daily treatment for migraine • Source: Nielsen Hobbs; the Pink Sheet | Shutterstock image

More from United Kingdom

More from Europe